Product Description
VE-1902 is a direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis. (Sourced from: https://www.verseon.com/news-efficacyanticoagulant_content.html)
Mechanisms of Action: Thrombin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Verseon
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Cardiovascular Abnormalities
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|